The rationale for this potential therapy is based on the information where SP-A is shown to modulate pathways either under baseline conditions [32,40] or in response to infection and/or ozone exposure [43,86,88] that are deemed important in COVID-19 disease [91]. Here, SFTPA2 is linked to infection.